Crinetics Pharmaceuticals (CRNX) 10-Q2022 Q1 Quarterly report

Filed: 12 May 22, 4:49pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: absorb, absorbed, accrual, Africa, agreed, analog, analyze, appoint, approach, Argentina, assume, began, behalf, beneficiary, Brazil, bundled, Canada, cancer, Chile, China, CLA, clarify, Colombia, colon, commencement, committee, constrained, constraint, context, counterparty, customer, depiction, depositary, designee, detailed, discount, distinct, Dr, Egypt, EMA, environment, Eurasia, explicit, fact, faithful, fourth, freestanding, fulfilled, good, greater, Hong, immaterial, independent, India, Indonesia, Inducement, influence, input, instrument, insufficient, investee, Israel, issuer, Japan, Kagaku, Kenkyusho, Kong, Korea, lag, licensee, ligand, MAD, Malaysia, margin, maximum, member, Mexico, mg, moderate, modification, mutually, NCCN, Network, nonrefundable, partially, percentage, Peru, portion, power, predetermined, previously, promised, proportionally, ratably, ratio, reconsideration, replace, reserved, reversal, SAD, Sanwa, seat, separate, separately, showed, Singapore, specialist, standalone, strategic, strength, subordinated, suggested, supply, symbolic, Taiwan, Thailand, Ukraine, unconsolidated, universal, unlimited, upfront, usage, variable, Venezuela, VIE, Vietnam, vote, voting, written, Zealand

Removed: Aid, beneficial, called, carryback, closed, computation, conversion, declared, declining, deduction, deferment, determination, Digestive, earlier, employer, EPS, extending, Health, initiated, Innovation, Institute, IPO, issue, Jaffray, line, managing, Morgan, NaNne, permitted, Piper, preliminary, presentation, receivable, reimbursable, Relief, SBIR, settled, smaller, social, source, SRL, technical, top, utilization

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CRNX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Crinetics Pharmaceuticals, Inc. (the “Company”) hereby certifies, to his knowledge, that:

(i) the accompanying Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ R. Scott Struthers, Ph.D.

R. Scott Struthers, Ph.D.

President and Chief Executive Officer

Date: May 12, 2022

CERTIFICATION OF CHIEF FINANCIAL OFFICER

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Marc J.S. Wilson

Marc J.S. Wilson

Chief Financial Officer

Date: May 12, 2022

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.